

with Rule 121 of the Rules of Practice. Accordingly, a clean copy of the amended paragraph follows below. In accordance with 37 C.F.R. § 1.121(b)(1)(iii), another version of the amended paragraph is also provided, on one or more separate pages at Exhibit Tab A, marked up to show all changes relative to the paragraph as originally filed. A Sequence Listing in paper and computer readable forms is also submitted herewith.

It is believed that no additional fees are required for this submission. However, should the U.S. Patent and Trademark Office determine that any fee is required or that any refund is due for this application, the Commissioner is hereby authorized and requested to charge the required fee(s) and/or credit the refund(s) due to Deposit Account No. 04-0100.

Please amend the application as follows:

IN THE SPECIFICATION:

Amend the paragraph starting at page 1, line 21 of the specification so that the amended paragraph reads as follows:

-- ACE acts on angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Pro-Phe-His-Leu) (SEQ ID NO: 1), which has been generated by digestion with renin, to release a dipeptide (His-Leu) from its C-terminal, thereby giving angiotensin II, which causes contraction of vascular smooth muscle and has strong hypertensive effect. --